Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...